191 |
Regulation and function of the leukocyte immunoglobulin-like receptors (LILRS) in rheumatoid arthritisHuynh, Owen Anthony, Medical Sciences, Faculty of Medicine, UNSW January 2008 (has links)
The Leukocyte Immunoglobulin-like Receptors (LILRs) are a family of receptors that is broadly expressed on all leukocytes and have the ability to regulate their function. A substantial amount of evidence suggests that LILRs may be involved in immune homeostasis but also immune dysregulation. We therefore studied the role of LILRs in relation to the autoimmune disease, rheumatoid arthritis (RA). RA is a chronic and systemic inflammatory disease involving inflammation of the joints affecting the synovial membrane, cartilage and bone. Much of the tissue damage is a result of an inappropriate immune response within the joint space caused by the unwarranted activation of leukocytes. Here were report that LILRA2 (an activating receptor) that has been previously shown to be highly expressed in the rheumatoid synovium, induces the production of pro-inflammatory cytokines TNF-α, IL-1, IL-6, IFN-γ and IL-10 in primary monocytes. These cytokines are known to have an important role in the pathogenesis of RA indicating a pathway by which LILRA2 exacerbates RA. Co-ligation of LILRB4 (an inhibitory receptor) with LILRA2 abolishes cytokine production suggesting that LILRB4 is able to suppress the function of LILRA2. Expression of both LILRA2 and LILRB4 are regulated by inflammatory cytokines and LPS, indicative of a feedback mechanism. There is also cross-talk between LILRs and TLR4 as co-stimulation with LPS and either LILRA2 or LILRB4 inhibits cytokine production. A differential expression of LILRs has also been identified on lymphocytes of patients with RA whereby an increase of LILRA1 (activating) and LILRB1 (inhibitory) expressing circulating lymphocytes is present in RA patients when compared to healthy control subjects. From these studies, we propose that LILRs have a functional role in RA by regulating local and systemic inflammation. The presence of LILRA2 in the RA joint is detrimental since its potent ability to induce inflammatory cytokines, particularly TNF-α, can initiate leukocyte recruitment and activation of proteases. Along with TLR4, LILRA2 and LILRB4 have the potential to moderate the innate immune system via regulation of cytokine production. Furthermore, suppression of LILRA2 function may serve as a therapeutic tool in many inflammatory diseases.
|
192 |
Lymphocyte-synovial microvascular endothelial cell interactions in experimental polyarthritis : a microassay for screening monoclonal antibodies that block adhesion / by Elizabeth-Anne Louise Farmer.Farmer, Elizabeth A. January 2004 (has links)
Bibliography: leaves 250-284. / xviii, 284 leaves : ill., plates (some col.) ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, School of Molecular and Biomedical Science, Discipline of Microbiology and Immunology, 2004
|
193 |
Genetic studies in rheumatoid arthritis : familial studies and analysis of relationships to atherothrombotic comorbidityÄrlestig, Lisbeth January 2012 (has links)
Background. Rheumatoid arthritis (RA) is an autoimmune disease mainly affecting the joints but has also extra articular manifestations and an increased cardiovascular (CV) co-morbidity. Rheumatoid factor (RF) and antibodies against citrullinated proteins/peptides (ACPA) are diagnostically important and are related to a more severe disease. The aetiology is unknown but RA is considered a complex disease caused by both genetic and environmental factors. The heritability is estimated to be 60% with the main contribution from the HLA region. The relative homogeneity of the population in northern Sweden due to low immigration and founder effects has shown to be suitable for genetic studies. Objectives. The aim of this thesis has been to identify genes contributing to the susceptibility of RA and the CV co-morbidity in particular. To achieve this, multi-case families from the four northern most counties of Sweden were collected for linkage studies to identify susceptibility genes. Association studies with genetic polymorphisms in genes, involved in inflammation or being of importance for atherothrombotic manifestations (ATM) in the general population, were performed in RA-patients concerning ATM e.g. myocardial infarction, angina pectoris with intervention, stroke/TIA, deep vein thrombosis/pulmonary embolism (DVT/PE) at follow-up. Methods & Results. 47 families with 134 affected and 216 unaffected relatives were included in a genome-wide linkage study (GWL) performed with microsatellite markers at an average of 10cM resolution analysed using ABI PRISM 3730 DNA sequencer and non-parametric multipoint linkage in the Merlin program. Eight linked loci were identified with HLA as the most significant and a novel region on chromosome 14. In a follow-up analysis on a custom Illumina chip, with 13 additional families, yielding a total of 198 affected and 197 unaffected relatives. The majority of the 1536 single nucleotide polymorphisms (SNPs) used in the Illumina follow-up analyses was focused on chromosome 14. Statistical analyses with linkage and transmission disequilibrium test narrowed the region to 4 cM, a region containing multiple plausible RA candidate genes (Paper I). In Paper II serum samples from 163 affected and 157 first degree relatives were analysed with EliA ACPA assay on ImmunoCAP250 for ACPA (IgA, IgG, IgM) and RF (IgA, IgM) isotypes. Both concentrations and frequencies were increased among the relatives compared with controls but lower compared with RA-patients and with a different relative distribution of the isotypes. The genetic contribution to ATM was studied in Paper III and IV using selected SNPs analysed using ABI PRISM 7900HT sequence detector system. In Paper III, RA-patients (n=467) were compared with age and sex matched controls (n=696) with respect to SNPs in tumor necrosis factor receptor II (TNFRII)(M196R), ß-fibrinogen -455 (G-455A), plasminogen activator inhibitor type-1 (PAI-1) (4G/5G) and Factor XIIIA (Val34Leu). Hypertension was predicted by TNFRII R allele and to a higher extent in combination with the A-allele in ß-fibrinogen. The 4G allele in PAI-1 was more frequent in patients with ischemic heart disease (IHD) and the FXIIIA Leu34 variant in patients with DVT/PE. In Paper IV, the minor allele of the polymorphism in growth differentiation factor 15 (GDF15) was found to be associated with RA (n=696) per se but also to ATM, a SNP in the 9p21.3 locus was also associated with ATM. A significant association to stroke was found in female patients homozygote for the minor allele of GDF15. Stoke among male patients was significantly associated with carrying the major allele of two SNPs in the CD40 gene. DVT/PE was associated with the minor allele of GDF15. Conclusion. A novel locus on chromosome 14 of importance for RA susceptibility in northern Sweden was found. The minor allele of TNFRII separately and together with the minor allele of ß-fibrinogen -455 was associated with hypertension and the 4G allele in PAI-1 was associated with IHD and the Leu34 variant was associated with DVT/PE in RA patients. The GDF15 minor allele was associated with RA per se, ATM and DVT/PE in RA patients and a genotype in the SNP on 9p21.3 was associated with ATM. Stroke among females was associated with GDF15 and stroke among males with two SNPs in CD40.
|
194 |
Pathogenetic factors of importance for the development and progression of rheumatoid arthritisKokkonen, Heidi January 2012 (has links)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation eventually leading to the destruction of cartilage and bone. The aetiopathogenesis is not completely understood, but previous studies have shown that the disease is multifactorial with genetic, environmental and hormonal factors involved. Immune cells, e.g., T- and B-cells, and macrophages, migrate into the joints, with increased expression of numerous soluble factors such as cytokines, chemokines and adhesion molecules functionally active both locally and systemically. Analyses of blood samples from the Medical Biobank in Umeå from individuals before the onset of symptoms of joint disease showed that anti-citrullinated protein/peptide antibodies (ACPA) preceded the development of disease by years and this finding has been confirmed by other studies. The aim of this thesis was to identify signs of activation of the immune system analysed as up-regulation of pro- and anti-inflammatory cytokines, sero-positivity for autoantibodies, and genetic factors identified as relevant for the development and disease progression of RA. The concentrations of 30 cytokines and chemokines were measured in blood samples from individuals before the onset of symptoms, and when diagnosed with RA, together with population-based matched controls using a multiplex system. The predictive value of different isotypes (IgG, IgA, and IgM) of ACPA and rheumatoid factor (RF) before onset of symptoms and different types of ACPA (e.g., mutated citrullinated vimentin, MCV) were analysed for disease development and progression in patients with early RA and controls from Northern Sweden. These factors were related to the genetic markers, HLA- shared epitope (SE) alleles and the 1858C/T polymorphism of the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene. In paper I, it was shown that in individuals who later developed RA (i.e., pre-patients) the levels of several cytokines and related factors that represent the adaptive immune system (Th1, Th2, and T regulatory cell related factors) were significantly elevated compared with controls, whereas, after the onset of disease the involvement of the immune system was more general and widespread. In paper II, the presence of different isotypes (IgM, IgA and IgG) of ACPA in pre-patients, patients and controls was evaluated showing that both the IgG and IgA isotype predicted the onset of RA by years with the IgG isotype having the highest predictive value. In paper III, the association of the 1858T variant of PTPN22 with RA was confirmed. Furthermore, the association was restricted to autoantibody positive disease and this variant was correlated with an earlier age for disease onset. In paper IV, anti-MCV antibodies were identified as being associated with a more severe disease course of RA, measured by disease activity score, erythrocyte sedimentation rate, and swollen joint count over time compared with anti-CCP2, anti-CCP3, and anti-CCP3.1 antibodies. In conclusion, individuals who later developed RA had increased concentrations of inflammatory markers reflecting an activation of the immune system years before the clinical symptoms of the disease developed. Also, the presence of ACPA of IgG and IgA isotype prior to disease onset predicted the development of RA. The PTPN22 1858T variant was associated with sero-positive RA and anti-MCV antibodies were associated with a higher inflammatory activity compared with anti-CCP2, -CCP3 and -CCP3.1 antibodies. These findings together present a possibility to better predict the development and progression of RA.
|
195 |
The Marketing Management for the New Medicine on the Market--The Study Focus on the Medicine of the Rheumatoid ArthritisWang, Jung-Tien 06 August 2007 (has links)
Abstract
As a matter of fact, for those producers in medicine industry who runs multi-national business, have to promote two to three kinds of new medicine on the market enabling to maintain two-digit growth. However, the new products (medicine) be certified for marketing is not able to follow the step and progress what have been researched and developed. The ratio of success for the research and development of new medicine as well as the quantity of the marketing for new medicine eventually become the most critical factor of determination for marketing value of all major international medicine producers.
This study will be preceded with discussion of reference document, collection of secondary information, and case study to describe the marketing strategy, that mainly focus on the analysis to the Rheumatoid Arthritis biological products and its relating information to further find out the ¡§Pattern of Successful Marketing for New Medicine¡¨. Moreover, it might sort out the key factor of successful marketing for many kinds of biological products for the Rheumatoid Arthritis. Eventually, the study is trying to propose the successful application of marketing for new medicine to maximize the opportunity of success and potentiality.
There are some key factors like planning and preparation for successful marketing of new medicine, which normally covers the complex of multi-professional filed. The combination of marketing is the tool to achieve the target market. These tools are divided into four classifications, named as ¡§Marketing 4 P¡¨: They are respectively Product, Price, Place and Promotion.
This study adopts 4 P of Promotion Management of Marketing to discuss the strategy of new medicine marketing and investigate the deployment of marketing strategy in Taiwanese medicine marketing. The study indicates the discussion of For 4 P can provide marketing personnel with a clear direction, to map out the thinking mode of complete strategy for new medicine marketing in order to diminish the resistance of marketing, and facilitate the success of new medicine Launch.
Key Words: New Medicine Launch, Marketing Strategy, Rheumatoid Arthritis, 4 P
|
196 |
"Delivering knowledge and advice" : Healthcare providers' experiences of their interaction with patients' management of rheumatoid arthritis.Bergsten, Ulrika, Bergman, Stefan, Fridlund, Bengt, Arvidsson, Barbro January 2011 (has links)
Rheumatic diseases are often chronic and involve a lifetime of suffering. The focus of rheumatology care is to support patients to manage their lives and master their disease. Healthcare providers and patients have different views on the consequences of living with rheumatic diseases and patients are reporting unmet healthcare needs. There is a need to integrate providers' perspective to develop the quality of rheumatology care. The aim was to explore healthcare providers' experiences of their interaction with patients in their management of RA. Interviews with 18 providers from different clinical settings were analysed in accordance with the grounded theory method. A core category; Delivering knowledge and advice was found to be the most important task and involved providing the patient with information about the disease and appropriate forms of treatment. Healthcare providers' attitudes and patients' responses influenced the outcome of the delivery of knowledge and advice and three dimensions emerged; completed delivery, adjusted delivery and failed delivery. There were differences in the providers' experiences in their interaction with patients as well as in reflections on their role as the delivering part. There could be difficulties in the interaction when patients' expectations and preferences were not taken into account when giving advice. These findings highlight the importance of developing rheumatology care, as no provider or patient benefits if the delivery of knowledge and advice becomes a failed delivery. The healthcare organization must acknowledge the difficulties involved in the interaction with patients in their management of RA and find methods to develop a more person-centred approach to care.
|
197 |
“Striving for a Good Life” : The Management of Rheumatoid Arthritis as Experienced by PatientsBergsten, Ulrika, Bergman, Stefan, Fridlund, Bengt, Arvidsson, Barbro January 2011 (has links)
Aim: To generate a theoretical model how patients experience their management of rheumatoid arthritis (RA) in everyday life.Method: An explorative design with the grounded theory approach was used by interviewing 16 informants with RA.Results: The generated theoretical model emerged in a core category- Striving for a good life with two categories; making use of personal resources and grasping for support from others, which formed the base of managing RA. When relating these categories together, four dimensions emerged which characterised patients’ different ways of managing RA: mastering, relying, struggling and being resigned.Discussion: The management of RA incorporated the use of personal resources and the grasping for support from others. Both self-management strategies and patients’ need of support were highlighted as aspects that were of importance when managing RA. Patients’ experiences of their need of support to manage RA give extended knowledge that is of importance for nurses and other healthcare providers. The relationship between patients and healthcare providers is always the key to a good encounter. Interventions to increase self-management in RA have to incorporate this knowledge when trying to increase patients’ self-efficacy and with their experience of support
|
198 |
MALDI MS Imaging zur Untersuchung von synovialem GewebeKriegsmann, Mark 23 July 2013 (has links) (PDF)
-
|
199 |
Polymorphismen in Kandidatengenen der Apoptose als genetische Risikofaktoren für Rheumatoide Arthritis / Polymorphisms in candidate genes of apoptosis pathways as genetic risk factors for rheumatoid arthritisOeser, Christian 26 June 2012 (has links) (PDF)
Die Rheumatoide Arthritis (RA) ist eine chronisch-entzündliche Systemerkrankung des Bindegewebes mit autoimmunem Charakter.
In dieser Studie wurden 7 Kandidatengene, welche in zentrale Abläufe der Apoptose involviert sind (CFLAR, XIAP, NFKB1, RELA, BCL2L1, FAS, FASLG), selektiert. Innerhalb dieser Gene wurden 23 Einzel-Basen-Polymorphismen (single nucleotide polymorphisms bzw. SNPs) sowie ein Insertions-Deletions-Polymorphismus in 300 französich-kaukasischen Individuen (100 RA-Trio-Familien) mittels Einzelbasenverlängerung (Single Base Extension bzw. SBE) in einer massenspektrometrischen Analyse durch MALDI-TOF-MS (Matrix Assisted Laser Desorption/Ionization–Time Of Flight Mass Spectrometry) genotypisiert. Die Auswahl der zu untersuchenden genetischen Polymorphismen erfolgte dabei unter Berücksichtigung einer möglichen funktionellen Bedeutung, bekannter Assoziationen mit RA oder anderer Autoimmunerkrankungen, der Lage im Gen sowie der genetischen Variabilität. Die Ergebnisse der Genotypisierung wurden genutzt um die Polymorphismen bzw. Kandidatengene mit Hilfe verschiedener statistischer Methoden auf ihre Assoziation mit RA hin zu untersuchen.
Die statistischen Analysen des SNPs CFLAR-rs7583529 zeigten hierbei einen nicht signifikanten Trend, wobei das minor Allel A gehäuft in RA Patienten vorkam. Das Ergebnis des Genotypen-Tests (Lathrop) für FAS-rs1800682 belegte einen protektiven Effekt für homozygote Träger des major Allels C (Lathrop pval = 0.045). Unterstützung für die gefundenen Trends bzw. Assoziationen von CFLAR-rs7583529 und FAS-rs1800682 boten Vergleiche mit Daten genomweiter Studien (NARAC/EIRA- und WTCCC-Studie).
In den Assoziationsanalysen von BCL2L1-rs3181073 zeigte sich ein protektiver Effekt des minor Allels A (TDT pval = 0.008, OR = 0.51 [0.3 – 0.9], OR pval = 0.014). Der Risikoeffekt des major Allels C spiegelte sich entsprechend im Lathroptest wider, welcher eine signifikante Anreicherung des homozygoten C/C-Genotyps in den Fällen anzeigte (Lathrop pval = 0.021).
Die gefundenen Assoziationen von FAS und BCL2L1 mit RA gehen mit der Hypothese konform, dass veränderte Abläufe sowohl im intrinsischen mitochondrialen (BCL2L1) als auch im extrinsischen (FAS) Weg der Apoptose in die Ätiologie der RA involviert sind. Die Ergebnisse dieser Arbeit sollten in einer zweiten unabhängigen Kohorte repliziert werden. In Folgestudien wäre es ebenfalls interessant, weitere SNPs der Kandidatengene zu genotypisieren, um die genetische Variabilität anhand der Haplotypen genauer zu analysieren. Sollten sich die o. g. Assoziationen bestätigen, sind im Weiteren funktionelle Studien bezüglich unterschiedlicher Genexpression oder verändertem Apoptoseverhalten von Zellen oder synovialem Gewebe von großem Interesse. / Rheumatoid arthritis (RA) is a chronic inflammatory systemic disease of the connective tissue with autoimmune character.
In this study, 7 candidate genes that are known to be involved in key processes of apoptosis (CFLAR, XIAP, NFKB1, REAL, Bcl2l1, FAS, FASLG) were selected. Within these genes, 23 single nucleotide polymorphisms (SNPs) and one insertion/deletion polymorphism were genotyped in a sample of 300 French Caucasian individuals (100 RA trio families) by means of Single Base Extension (SBE) and MALDI-TOF (Matrix Assisted Laser Desorption /Ionization–Time Of Flight) mass spectrometry analysis. The possible functional significance, known associations with RA or other autoimmune diseases, the location in the gene and genetic variability were taken into account during the selection of genetic polymorphisms. The SNP genotyping results were used to analyse associations of polymorphisms or candidate genes with RA by applying various statistical methods.
Analysis of the SNP CFLAR-rs7583529 showed a non-significant trend toward increased frequency of the minor allele A in RA patients. The genotypic test (Lathrop) of FAS-rs1800682 revealed a protective effect for homozygous carriers of major allele C (Lathrop pval = 0.045). Data of genome-wide studies (NARAC/EIRA- and WTCCC study) provided further support for association of CFLAR-rs7583529 and FAS-rs1800682 like confirmed in this study.
Association analysis of Bcl2l1-rs3181073 showed a protective effect of the minor allele A (TDT pval = 0.008, OR = 0.51 [0.3 - 0.9], pval OR = 0.014). The genotypic Lathrop-test in turn revealed a corresponding risk effect for homozygous C/C genotype carriers (Lathrop pval = 0.021).
Within this study, associations of the apoptosis genes FAS and Bcl2l1 with RA were found out. These results further indicate that changes of the intrinsic mitochondrial (Bcl2l1) and extrinsic (FAS) apoptosis pathway are possibly involved in the etiology of RA. For confirmation, results of this study should be replicated in a larger independent cohort. It would also be of interest to analyze the genetic variability based on specific haplotypes of additional SNPs within candidate genes. If the aforementioned associations are confirmed, functional studies with regard to different gene expression or changed apoptosis initiation in cells or synovial tissue would be of interest.
|
200 |
Anti-arthritic effects of marine-derived compound obtained from gorgonian coralSun, Yu-min 19 July 2010 (has links)
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs but principally attacks synovial joints. All the symptoms of RA are mainly caused by cell inflammation, which results in cellular infiltration and synovial hyperplasia, finally leading to severe bone erosion. Existing drugs (steroids, non-steroid antiinflammatory drugs, disease-modifying anti-rheumatic drugs, etc.) can attenuate the symptoms of RA; however, these drugs also have many side effects. Therefore, it is necessary to discover new drugs for RA. Excavatolide B (Exc-B) is derived from the gorgonian coral. In our preliminary observations, Exc-B strongly inhibited lipopolysaccharide (LPS)-induced proinflammatory inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression in RAW264.7 macrophages. The present study also showed that Exc-B significantly attenuates the expressions of osteoclast-like gene, cathepsin K, and matrix metalloproteinase (MMP)-9 in LPS-treated RAW 264.7 cells. Moreover, in the adjuvant-induced RA animal model, Exc-B effectively reduced the swelling and arthritic index from the morphological viewpoint as well as reduced bone erosion and synovial hyperplasia from the pathological viewpoint. Our data indicates that Exc-B can inhibit disease progression in RA. Hence, Exc-B may serve as a useful therapeutic agent for the treatment of RA.
|
Page generated in 0.0582 seconds